Johnson & Johnson's financial profile following the Kenvue separation is that of a focused, high-margin pharmaceutical and medical device company with exceptional cash generation, a strong balance sheet, and a capital allocation strategy oriented toward R&D investment, bolt-on acquisitions, and consistent shareholder returns. Total revenue for 2023 (from continuing operations, excluding Kenvue) was approximately $85.2 billion, with Innovative Medicine contributing approximately $55 billion and MedTech approximately $30 billion. This revenue base reflects one of the broadest and most durable revenue portfolios in healthcare — no single product represents more than approximately 12% of total revenue, and geographic diversification across the US (approximately 55%), international markets (approximately 45%) provides additional resilience. Operating margins in the Innovative Medicine segment, reflecting J&J's premium positioning and pricing power for genuinely innovative biologics and specialty pharmaceuticals, are among the highest in the pharmaceutical industry. Adjusted operating margins of 35-40% on pharmaceutical revenue translate to substantial free cash flow generation that funds R&D investment while providing significant shareholder returns. MedTech margins (approximately 20-25% adjusted operating margin) are lower but still above the medical device industry average, reflecting J&J's premium product positioning and the recurring nature of implant revision revenue. Free cash flow generation has consistently exceeded $15 billion annually, providing extraordinary capital deployment flexibility. J&J has maintained a AAA credit rating — one of only two US companies to hold this rating alongside Microsoft — a distinction that reflects both financial strength and the consistency of cash generation through economic and therapeutic cycles. This financial stability enables J&J to make long-duration R&D and capital investments that shorter-horizon competitors cannot sustain. The pipeline of acquisitions has been a significant capital deployment channel. J&J's acquisition of Shockwave Medical (2024) for approximately $13.1 billion, Abiomed (2022) for approximately $16.6 billion, and multiple smaller acquisitions in oncology, immunology, and MedTech reflect a consistent strategy of acquiring clinical-stage or commercial-stage assets that accelerate the therapeutic portfolio beyond what internal discovery alone would produce. These acquisitions are funded from operating cash flow and debt issuance at J&J's AAA-rated borrowing cost — providing a capital cost advantage in acquisition competition against smaller pharmaceutical companies. The biosimilar erosion of Stelara beginning in 2023-2024 — with multiple biosimilar approvals reducing revenue from approximately $10 billion annual peak — represents the most significant near-term revenue headwind. Management has been transparent about this expected erosion and has positioned the Innovative Medicine segment's growth story around the offsetting trajectory of Darzalex, Tremfya, Carvykti, and new pipeline launches.